Cardarine comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-30. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Guzmán G. (1983). The genus Psilocybe: A Systematic Revision of the Known Species Including the History, Distribution and Chemistry of the Hallucinogenic Species. Nova Hedwigia Beihefte. Vol. 74. Berlin: J. Cramer. ISBN 978-3-7682-5474-8. Bresinsky A, Besl H (1989). A Colour Atlas of Poisonous Fungi: a Handbook for Pharmacists, Doctors, and Biologists. London, UK: Manson Publishing Ltd. ISBN 978-0-7234-1576-3. Stamets P. (1996). Psilocybin Mushrooms of the World: An Identification Guide. Berkeley, California: Ten Speed Press. ISBN 978-0-89815-839-7. Gartz J. (1997). Magic Mushrooms Around the World. Los Angeles, California: LIS Publications. ISBN 978-0-9653399-0-2.
=== Role in parturition === CRH is synthesized by the placenta and seems to determine the duration of pregnancy. Levels rise towards the end of pregnancy just before birth and current theory suggests three roles of CRH in parturition:
One reason why it is important to study the nature of UCMs is that some have been shown to contain toxic components, but only a small range of known petrogenic toxicants, such as the USEPA list of 16 polycyclic aromatic hydrocarbons (PAHs), tend to be routinely monitored in the environment. Analysis of the hydrocarbon fraction of crude oils by GC reveals a complex mixture containing many thousands of individual components. Components that are resolved by GC have been extensively studied e.g. However, despite the application of many analytical techniques the remaining components have, until very recently, proved difficult to separate due to the large numbers of co-eluting compounds. Gas chromatograms of mature oils have prominent n-alkane peaks which distract attention from the underlying unresolved complex mixture (UCM) of hydrocarbons often referred to as the ‘hump’. Processes such as weathering and biodegradation result in a relative enrichment of the UCM component by removal of resolved components and the creation of new compounds. It has been shown that both resolved and unresolved components of oils are subject to concurrent biodegradation, i.e. it is not a sequential process, but due to the recalcitrant nature of some components, the rates of biodegradation of individual compounds greatly varies. The UCM fraction often represents the major component of hydrocarbons within hydrocarbon-polluted sediments (see reference therein) and biota e.g.
Sources: en.wikipedia.org
== Definition == According to the procedure outlined by Kendrick, the mass of CH2 is defined as exactly 14 Da, instead of the IUPAC mass of 14.01565 Da. To convert an IUPAC mass of a particular compound to the Kendrick mass, the equation
In 1983, the Reagan administration intervened in the multisided Lebanese Civil War, invaded Grenada, bombed Libya and backed the Central American Contras, anti-communist paramilitaries seeking to overthrow the Soviet-aligned Sandinista government in Nicaragua. While Reagan's interventions against Grenada and Libya were popular in the United States, his backing of the Contra rebels was mired in controversy. The Reagan administration's backing of the military government of Guatemala during the Guatemalan Civil War, in particular the regime of Efraín Ríos Montt, was also controversial. Meanwhile, the Soviets incurred high costs for their own foreign interventions. Although Brezhnev was convinced in 1979 that the Soviet war in Afghanistan would be brief, Muslim guerrillas, aided by the US, China, Britain, Saudi Arabia, and Pakistan, waged a fierce resistance against the invasion. The Kremlin sent nearly 100,000 troops to support its puppet regime in Afghanistan, leading many outside observers to dub the war "the Soviets' Vietnam". However, Moscow's quagmire in Afghanistan was far more disastrous for the Soviets than Vietnam had been for the Americans because the conflict coincided with a period of internal decay and domestic crisis in the Soviet system. A senior US State Department official predicted such an outcome as early as 1980, positing that the invasion resulted in part from a:
=== December === December 1, 2008: United States The US economy has been in recession since December 2007, the National Bureau of Economic Research announced in December 2008. The bureau is a private research institute widely regarded as the official arbiter of US economic cycles. It said a 73-month economic expansion had come to an end. The Bureau stated that the deteriorating labour market throughout 2008 provided reason to state the commencement of the recession as December 2007.
==== Relapsing-remitting multiple sclerosis ==== Many disease-modifying medications have been approved for RRMS; and some are highly effective at decreasing the number of attacks. Highly effective medications include monoclonal antibodies directed at CD20-expressing B cells (administred by injection or infusion, e.g. rituximab), natalizumab (an integrin) or alemtuzumab, which depletes white blood cells more broadly. Treatment of CIS with interferons decreases the chance of progressing to clinical MS. In general, aggressive treatment in the early stages of MS produces the best long-term outcomes. The relative effectiveness of different treatments is unclear, as most have only been compared to placebo or a small number of other therapies. There is high confidence that natalizumab, cladribine, or alemtuzumab are decreasing relapses over two years for people with RRMS. Natalizumab and interferon beta-1a (Rebif) may reduce relapses compared to both placebo and interferon beta-1a (Avonex) while Interferon beta-1b (Betaseron), glatiramer acetate, and mitoxantrone may also prevent relapses. There is moderate confidence that a two-year treatment with natalizumab slows disability progression for people with RRMS. All medications are associated with adverse effects that may influence their risk-to-benefit profiles. Ublituximab was approved for medical use in the United States in December 2022.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.